<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006341</url>
  </required_header>
  <id_info>
    <org_study_id>1160-0219</org_study_id>
    <nct_id>NCT03006341</nct_id>
  </id_info>
  <brief_title>Validation of Predictors of OAC Initiation Using EMR Data</brief_title>
  <official_title>Validation of Predictors for Oral Anticoagulant Medication Choice Using EMR Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are, first, to identify select clinical covariates from
      electronic medical records (EMR) that might be associated with initiation of oral
      anticoagulant medications (dabigatran or warfarin) in patients with non-valvular atrial
      fibrillation (NVAF) at risk for stroke; second, to quantify the association between EMR-based
      clinical characteristics and patterns of insurance claims; third, to assess the potential for
      unmeasured confounding in dabigatran vs warfarin comparative effectiveness and safety studies
      based on administrative claims databases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Actual">May 9, 2017</completion_date>
  <primary_completion_date type="Actual">May 9, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Obesity</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Smoking</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol consumption</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal renal function</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding history or predisposition</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal function (estimated GFR closest to index dispensing)</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Creatinine (closest to index dispensing)</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal liver function</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of atrial fibrillation</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>History of adherence: non-adherent/adherent</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncontrolled Hypertension</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congestive Heart Failure</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prior Transient Ischemic Attack</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperlipidemia</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAS-BLED Score</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antiplatelets or Non-steroidal Anti-inflammatory Drugs</measure>
    <time_frame>within 1 month</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">140187</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate</arm_group_label>
    <description>NVAF patients initiating dabigatran etexilate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <description>NVAF patients initiating warfarin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>observed upto 12 months</description>
    <arm_group_label>Dabigatran etexilate</arm_group_label>
    <other_name>PRADAXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Observed upto 12 months</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a recorded diagnosis of atrial fibrillation without evidence of valvular
        etiology and at risk for stroke
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First dispensing of warfarin or dabigatran between October 2010 and December 2014

          -  Diagnosis of atrial fibrillation

          -  ≥ 12 months enrolment in the database preceding the date of the first dispensing

          -  Age ≥ 18

          -  CHA2DS2-VASc score ≥ 1

        Exclusion Criteria:

          -  Prior use of oral anticoagulation

          -  Evidence of valvular atrial fibrillation

          -  Missing or ambiguous age or sex information

          -  Patients with a nursing home stay during baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2016</study_first_submitted>
  <study_first_submitted_qc>December 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 4, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

